Hematology

Latest News

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Researchers Identify New Cancer Cell That Is Key to Relapse in AML
September 23rd 2018

Researchers Identify New Cancer Cell That Is Key to Relapse in AML

Laura Joszt, MA
Cancer-regenerating cells that arise after chemotherapy have been identified as a new type of cancerous cell that is responsible for the return of acute myeloid leukemia (AML) after remission.
Patient Stress Is Linked With Cancer Cell Proliferation and Elevated Cytokines in CLL
September 19th 2018

Patient Stress Is Linked With Cancer Cell Proliferation and Elevated Cytokines in CLL

Kelly Davio
While it is well understood that psychological distress is a major side effect of cancer and its treatment, and that stress can have a strong impact on patients’ quality of life, a new study indicated that stress is linked with markers of more advanced disease in patients with chronic lymphocytic leukemia (CLL), the most common form of leukemia among adults.
Insurance Status Matters in Follicular Lymphoma, Study Finds
September 18th 2018

Insurance Status Matters in Follicular Lymphoma, Study Finds

Mary Caffrey
Lower socioeconomic status is associated with poor survival in lymphoma.
Hispanic Children With ALL at Greater Risk of Neurotoxicity During Treatment
September 16th 2018

Hispanic Children With ALL at Greater Risk of Neurotoxicity During Treatment

Laura Joszt, MA
Children of Hispanic ethnicity have a higher risk of developing neurotoxicity when they are treated with methotrexate for acute lymphoblastic leukemia (ALL) compared with non-Hispanic white children.
This Week in Managed Care: September 14, 2018
September 14th 2018

This Week in Managed Care: September 14, 2018

This week, the top managed care news included medical groups asking CMS to halt or slow down its plans to cut physician reimbursement for evaluation and management services; the Senate weighs a package of bills to combat the opioid epidemic; new research shows the Affordable Care Act pushed the uninsured rate down to 10%.
Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells
September 13th 2018

Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells

Laura Joszt, MA
Researchers at Baylor College of Medicine have found that preventing a mutated protein from leaving the nucleus and traveling to the cytoplasm of the cell can help inhibit the growth of leukemic cells in acute myeloid leukemia.
Prescription Drug Coverage Improved Survival for Patients With MM
September 9th 2018

Prescription Drug Coverage Improved Survival for Patients With MM

Laura Joszt, MA
Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.
Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma
September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA
Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
FDA Approves New Drug for Adults and Adolescents With Hemophilia A
September 2nd 2018

FDA Approves New Drug for Adults and Adolescents With Hemophilia A

Laura Joszt, MA
A new long-acting treatment for hemophilia A has been approved for previously treated patients, aged 12 years and older. Bayer’s Jivi was also approved for on-demand treatment and the perioperative management of bleeding in the same population.
Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers
August 31st 2018

Patients With Blood Cancer Less Likely to Understand Diagnosis Compared With Other Cancers

Laura Joszt, MA
A survey of patients in the United Kingdom who were diagnosed with cancer found that patients with blood cancers were the least likely to say they completely understood what was wrong when the doctor explained it. They were also less likely to say that their treatment options were explained before treatment started compared with patients with other cancers.
Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population
August 28th 2018

Childbirth Rates for Female Survivors of Hodgkin Lymphoma Similar to General Population

Laura Joszt, MA
As cure rates for young patients with Hodgkin lymphoma (HL) improve, the historically negative impact of treatments has to be considered. However, a new study has found that over time, childbearing rates for female survivors of HL have improved to the point of approaching the rates of the general population.
Dose-Confirmation Study for Hemophilia B Gene Therapy Underway
August 24th 2018

Dose-Confirmation Study for Hemophilia B Gene Therapy Underway

Laura Joszt, MA
The first patient has been treated in a phase 2b dose-confirmation study of AMT-061, an investigational gene therapy for the treatment of patients with severe and moderately severe hemophilia B. Once the dosing of AMT-061 is confirmed, the safety and efficacy of the therapy will be evaluated in the global phase 3 HOPE-B clinical trial.
Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy
August 22nd 2018

Tracking ctDNA Levels Can Quickly Predict Response to Lymphoma Therapy

Laura Joszt, MA
A blood test that tracks the rise and fall of circulating tumor DNA (ctDNA) levels can predict how patients with diffuse large B-cell lymphoma will respond to therapy within days of starting treatment.
AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma
August 16th 2018

AI Platform Can Identify Personalized Drug Combinations to Treat Multiple Myeloma

Laura Joszt, MA
A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.
New Biologic Approved to Treat 2 Rare Types of Non-Hodgkin Lymphoma
August 13th 2018

New Biologic Approved to Treat 2 Rare Types of Non-Hodgkin Lymphoma

Laura Joszt, MA
The FDA has approved a new drug to treat 2 rare types of non-Hodgkin lymphoma based on phase 3 clinical trial results that found mogamulizumab-kpkc improved progression-free survival and had a higher overall response rate compared with the chemotherapy vorinostat.
Progress Has Eased Burden on Patients With Blood Cancers, but More Change Is Needed, LLS Reports
August 10th 2018

Progress Has Eased Burden on Patients With Blood Cancers, but More Change Is Needed, LLS Reports

Laura Joszt, MA
A progress report from the Leukemia & Lymphoma Society highlighted policy measures that have eased the burden on patients, but also noted where more work is needed.
AYAs With Hodgkin Lymphoma Face Additional Burdens With Current Clinical Trial Designs
August 8th 2018

AYAs With Hodgkin Lymphoma Face Additional Burdens With Current Clinical Trial Designs

Laura Joszt, MA
Advances in Hodgkin lymphoma treatment has led to high survival rates, but adolescents and young adults, who represent the largest age group affected by the disease, face lifelong morbidities from clinical trials. New analytic methods could help inform future protocol changes.
AYAs With Blood Cancers Face Unique Psychosocial Issues That Impact Quality of Life
August 3rd 2018

AYAs With Blood Cancers Face Unique Psychosocial Issues That Impact Quality of Life

Laura Joszt, MA
In addition to survival among adolescents and young adults (AYAs) with hematological malignancies lagging behind that of children and older adults, AYAs also face unique challenges related to their physical, psychosocial, and economic circumstances.
Interventions for AML After Relapse Work Best in Patients Who Achieved CR
July 30th 2018

Interventions for AML After Relapse Work Best in Patients Who Achieved CR

Laura Joszt, MA
Treatment options for patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) are limited, but those who are able to receive intensive interventions receive a second allo-HCT or donor lymphocyte infusion. A study in JAMA Oncology sought to compare the 2 options for patients who relapse.
Addressing Unmet Needs in Multiple Myeloma
July 25th 2018

Addressing Unmet Needs in Multiple Myeloma

Second Myeloma Relapse and Beyond: Upcoming Strategies
July 25th 2018

Second Myeloma Relapse and Beyond: Upcoming Strategies

Selecting Treatment at First Relapse of Multiple Myeloma
July 25th 2018

Selecting Treatment at First Relapse of Multiple Myeloma

Optimizing Maintenance Therapy in Multiple Myeloma
July 25th 2018

Optimizing Maintenance Therapy in Multiple Myeloma

Frontline Therapy's Impact on Later Treatment in MM
July 25th 2018

Frontline Therapy's Impact on Later Treatment in MM

Multiple Myeloma: Frontline Daratumumab Combinations
July 25th 2018

Multiple Myeloma: Frontline Daratumumab Combinations

Frontline Therapy Options for Multiple Myeloma
July 25th 2018

Frontline Therapy Options for Multiple Myeloma

Approaching Upfront Treatment for Multiple Myeloma
July 25th 2018

Approaching Upfront Treatment for Multiple Myeloma

Advent of Combination Strategies in Multiple Myeloma
July 25th 2018

Advent of Combination Strategies in Multiple Myeloma

Treating Multiple Myeloma at Second Relapse and Beyond
July 25th 2018

Treating Multiple Myeloma at Second Relapse and Beyond

Treating Multiple Myeloma at First Relapse
July 25th 2018

Treating Multiple Myeloma at First Relapse

<1
...
161718192021222324
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo